ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Duke Physician, BM, Patients, Lobby For Reimbursement

October 22, 1993

Clinical Trials Approved By NCI Last Month Listed

February 22, 2002

Director’s Advisory Committee to Make Advice “Kosher”

March 7, 1997

Bypass Budget Will Call For 15-percent Increase

February 18, 2011

In Brief: Waldmann, Fisher Win Top Miken Prizes Of $250,000 Each, Six Others Get $50,000

November 10, 1989

FDA Approved 88% Of Cancer Applications Since Oncology Office Opened In 2005.

July 3, 2008